Webinar Summary
The standard preclinical model paradigm is shifting. With the enactment of the FDA Modernization Act 3.0, the global regulatory framework officially champions the utilization of non-animal models (NAMs) to evaluate next-generation therapeutics. Yet, many drug development pipelines remain hampered by limited mechanism-of-action insights and physiological mismatches inherent to 2D cultures and animal screens.
Curi Bio’s Custom Scientific Services function as a dedicated, white-glove extension of your internal R&D department. By combining structural tissue engineering with automated functional phenotyping, our platforms capture real-time human physiological responses that standard endpoints miss.
In this webinar, we break down exactly how our contract research infrastructure supports high-value discovery, safety, and potency programs:
Off-The-Shelf Human Baseline Profiles: Evaluate therapeutic intervention or vector delivery on human tissues carrying clinically relevant mutations in common neuromuscular or cardiac diseases, including DMD, DM1, and MYBPC3.
Advanced Multi-Parametric Screening: See how we execute repeated dosing, washout tracking, and multi-lineage co-cultures to characterize complex cellular interactions.
Regulatory-Ready Operational Frameworks: Review the robust, standardized datasets compiled by our PhD scientists operating under predictable Fee-for-Service (FFS) and flexible Full-Time Equivalent (FTE) frameworks.
Who Should Attend: Lab leaders, principal scientists, and project directors in safety pharmacology, translational medicine, gene therapy, and neuromuscular disease modeling looking to update their workflows with high-efficiency non-animal models.
Join Dr. Thomas Leahy and Dr. Christal Worthen to learn how you can leverage these advanced 3D tissue models and assays to generate decision-driving data for your research and therapeutic discovery pipelines.
Date & Time
Tuesday July 14, 2026 at 8:00-9:00am PDT (11:00am EDT / 5:00pm CET)
Speaker Details
Dr. Christal Worthen
Sr. Director, Research & Development at Curi Bio
Dr. Christal Worthen
Sr. Director, Research & Development at Curi Bio
Dr. Worthen is Senior Director of R&D at Curi Bio, where she leads development and application of human iPSC-derived tissue models for disease modeling, drug discovery, and translational research. She works closely with biopharma partners to design studies that leverage Curi Bio's cardiac, skeletal muscle, and neuromuscular platforms to answer complex preclinical questions.
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Leahy is a Field Applications Scientist at Curi Bio with a background in musculoskeletal and cardiovascular research, biomechanics, and 3D tissue engineering. He supports the adoption of Curi Bio’s technologies by collaborating with internal scientists and partnering directly with customers to expand applications across cardiac, skeletal muscle, and neuromuscular research.
Register Now to Secure Your Spot
Submit the form below to register for this live webinar + Q&A session. Registration will close 24 hours before the event.
Please contact us with any questions or concerns.